Corcept Therapeutics Inc (CORT): who owns it and who trades it
As of Nov 16, 2026, CORT insiders reported 107 open-market sales worth $97.7M and 2 purchases worth $3.3M in the last 12 months, with 9% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sean Maduck (See Remarks), with $25M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Corcept Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CORT
420 funds and institutions reported CORT shares worth $7.2B at the end of Q2 2026, about 78% of the company. The largest holder is BlackRock, Inc. with 11.6%.
Funds and institutions (13F) 78%Everyone else 22%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 12.43M | 11.58% | $1.1B | +2% |
| Ingalls & Snyder LLC | 7.93M | 7.39% | $690M | +4% |
| Renaissance Technologies LLC | 5.26M | 4.90% | $457M | -7% |
| Vanguard Portfolio Management LLC | 5.04M | 4.70% | $439M | +5% |
| Vanguard Capital Management LLC | 4.17M | 3.89% | $363M | +2% |
| Parallel Advisors, LLC | 3.96M | 3.69% | $345M | -0% |
| FMR LLC (Fidelity) | 3.34M | 3.11% | $290M | +5% |
| State Street Corp | 3.28M | 3.05% | $285M | +2% |
| AQR Capital Management LLC | 2.58M | 2.41% | $225M | +536% |
| Geode Capital Management, LLC | 2.53M | 2.36% | $220M | -7% |
| First Trust Advisors LP | 1.83M | 1.70% | $159M | -16% |
| Tang Capital Management LLC | 1.50M | 1.40% | $130M | No change |
| UBS Group AG | 1.38M | 1.28% | $120M | +1% |
| Dimensional Fund Advisors LP | 1.32M | 1.23% | $115M | -15% |
| Charles Schwab Investment Management Inc | 1.16M | 1.08% | $101M | +3% |
| Sixth Street Partners Management Company, L.P. | 1.16M | 1.08% | $101M | – |
| Morgan Stanley | 1.14M | 1.06% | $98.9M | +12% |
| D. E. Shaw & Co., Inc. | 883,001 | 0.82% | $76.8M | -25% |
| Cerity Partners LLC | 797,119 | 0.74% | $69.3M | +9% |
| Mpm Bioimpact LLC | 771,028 | 0.72% | $67M | -22% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CORT insiders reported $3.3M of open-market purchases and $97.7M of sales. 9% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Daniel N Swisher JR | Director | Sale plan | 1,500 | $74.07 | $111K | Form 4 |
| Nov 3, 2026 | Sean Maduck | Other | Sale plan | 8,617 | $82.02 | $707K | Form 4 |
| Nov 3, 2026 | Sean Maduck | Other | Sale plan | 4,542 | $82.68 | $376K | Form 4 |
| Nov 2, 2026 | Roberto Wandenkolk Vieira | President | Sale plan | 6,657 | $80.73 | $537K | Form 4 |
| Nov 2, 2026 | Roberto Wandenkolk Vieira | President | Sale plan | 1,676 | $81.52 | $137K | Form 4 |
| Nov 2, 2026 | Sean Maduck | Other | Sale plan | 11,841 | $81.42 | $964K | Form 4 |
| Oct 15, 2026 | James N Wilson | Director | Sale plan | 6,654 | $114.48 | $762K | Form 4 |
| Oct 15, 2026 | James N Wilson | Director | Sale plan | 3,046 | $115.39 | $351K | Form 4 |
| Oct 15, 2026 | James N Wilson | Director | Sale plan | 300 | $116.30 | $34.9K | Form 4 |
| Oct 2, 2026 | Sean Maduck | See Remarks | Sale plan | 15,843 | $116.12 | $1.8M | Form 4 |
| Oct 2, 2026 | Sean Maduck | See Remarks | Sale plan | 8,744 | $116.55 | $1M | Form 4 |
| Oct 2, 2026 | Joseph Douglas Lyon | See Remarks | Sale plan | 4,446 | $115.70 | $514K | Form 4 |
| Oct 2, 2026 | Joseph Douglas Lyon | See Remarks | Sale plan | 4,744 | $116.54 | $553K | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk Vieira | President | Sale plan | 1,100 | $114.52 | $126K | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk Vieira | President | Sale plan | 2,086 | $115.73 | $241K | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk Vieira | President | Sale plan | 5,147 | $116.58 | $600K | Form 4 |
| Oct 1, 2026 | Sean Maduck | See Remarks | Sale plan | 413 | $115.54 | $47.7K | Form 4 |
| Oct 1, 2026 | Joseph Douglas Lyon | See Remarks | Sale plan | 810 | $115.40 | $93.5K | Form 4 |
| Sep 16, 2026 | Roberto Wandenkolk Vieira | President | Sale | 296 | $100.82 | $29.8K | Form 4 |
| Sep 15, 2026 | James N Wilson | Director | Sale | 2,800 | $111.70 | $313K | Form 4 |
| Sep 15, 2026 | James N Wilson | Director | Sale | 400 | $110.84 | $44.3K | Form 4 |
| Sep 15, 2026 | James N Wilson | Director | Sale | 6,800 | $110.27 | $750K | Form 4 |
| Sep 14, 2026 | Joseph Douglas Lyon | See Remarks | Sale | 7,812 | $113.32 | $885K | Form 4 |
| Sep 14, 2026 | Joseph Douglas Lyon | See Remarks | Sale | 2,188 | $114.12 | $250K | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | President | Sale | 1,225 | $115.44 | $141K | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | President | Sale | 5,621 | $114.58 | $644K | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | President | Sale | 1,606 | $113.72 | $183K | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | President | Sale | 1,537 | $111.37 | $171K | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | President | Sale | 23,770 | $110.70 | $2.6M | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | President | Sale | 23,600 | $109.35 | $2.6M | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk Vieira | President | Sale | 974 | $112.40 | $109K | Form 4 |
| Sep 1, 2026 | Sean Maduck | See Remarks | Sale | 11,730 | $113.94 | $1.3M | Form 4 |
| Sep 1, 2026 | Sean Maduck | See Remarks | Sale | 2,281 | $115.61 | $264K | Form 4 |
| Sep 1, 2026 | Sean Maduck | See Remarks | Sale | 10,989 | $114.71 | $1.3M | Form 4 |
| Aug 26, 2026 | Kimberly Park | Director | Sale | 26,685 | $122.55 | $3.3M | Form 4 |
| Aug 25, 2026 | Sean Maduck | See Remarks | Sale | 5,870 | $126.06 | $740K | Form 4 |
| Aug 25, 2026 | Sean Maduck | See Remarks | Sale | 25,085 | $125.47 | $3.1M | Form 4 |
| Aug 18, 2026 | David L Mahoney | Director | Sale | 91,167 | $118.24 | $10.8M | Form 4 |
| Aug 18, 2026 | David L Mahoney | Director | Sale | 400 | $119.64 | $47.9K | Form 4 |
| Aug 18, 2026 | David L Mahoney | Director | Sale | 7,055 | $118.88 | $839K | Form 4 |
| Aug 18, 2026 | David L Mahoney | Director | Sale | 4,984 | $117.47 | $585K | Form 4 |
| Aug 17, 2026 | Gary Charles Robb | Chief Business Officer | Sale | 10,000 | $116.26 | $1.2M | Form 4 |
| Aug 14, 2026 | Sean Maduck | See Remarks | Sale | 3,664 | $114.49 | $419K | Form 4 |
| Aug 14, 2026 | James N Wilson | Director | Sale | 3,053 | $110.49 | $337K | Form 4 |
| Aug 14, 2026 | James N Wilson | Director | Sale | 2,279 | $112.64 | $257K | Form 4 |
| Aug 14, 2026 | James N Wilson | Director | Sale | 4,668 | $111.44 | $520K | Form 4 |
| Aug 10, 2026 | Sean Maduck | See Remarks | Sale | 1,031 | $114.52 | $118K | Form 4 |
| Aug 10, 2026 | William Guyer | Chief Development Office | Sale | 11,530 | $113.18 | $1.3M | Form 4 |
| Aug 10, 2026 | William Guyer | Chief Development Office | Sale | 4,770 | $114.04 | $544K | Form 4 |
| Aug 4, 2026 | William Guyer | Chief Development Office | Sale | 3,700 | $113.12 | $419K | Form 4 |
| Aug 3, 2026 | Sean Maduck | See Remarks | Sale | 20,305 | $114.70 | $2.3M | Form 4 |
| Aug 3, 2026 | Joseph Douglas Lyon | See Remarks | Sale | 1,540 | $114.16 | $176K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 7,089 | $116.96 | $829K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 8,267 | $117.93 | $975K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 4,783 | $118.73 | $568K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 8,103 | $119.95 | $972K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 1,001 | $120.67 | $121K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 8,956 | $106.96 | $958K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 400 | $108.46 | $43.4K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 2,202 | $110.03 | $242K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 600 | $110.95 | $66.6K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 4,700 | $113.18 | $532K | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 15,477 | $114.96 | $1.8M | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 14,222 | $115.87 | $1.6M | Form 4 |
| Jul 30, 2026 | Atabak Mokari | CFO | Sale | 4,200 | $105.54 | $443K | Form 4 |
| Jul 15, 2026 | James N Wilson | Director | Sale | 1,079 | $86.78 | $93.6K | Form 4 |
| Jul 15, 2026 | James N Wilson | Director | Sale | 3,969 | $87.74 | $348K | Form 4 |
| Jul 15, 2026 | James N Wilson | Director | Sale | 1,978 | $89.49 | $177K | Form 4 |
| Jul 15, 2026 | James N Wilson | Director | Sale | 2,974 | $88.81 | $264K | Form 4 |
| Jul 15, 2026 | Atabak Mokari | CFO | Sale | 101 | $89.43 | $9K | Form 4 |
| Jul 15, 2026 | Atabak Mokari | CFO | Sale | 3,520 | $88.30 | $311K | Form 4 |
| Jul 15, 2026 | Atabak Mokari | CFO | Sale | 28,460 | $87.89 | $2.5M | Form 4 |
| Jul 15, 2026 | Atabak Mokari | CFO | Sale | 7,919 | $86.78 | $687K | Form 4 |
| Jul 7, 2026 | William Guyer | Chief Development Office | Sale | 19,048 | $93.11 | $1.8M | Form 4 |
| Jul 7, 2026 | William Guyer | Chief Development Office | Sale | 952 | $93.54 | $89.1K | Form 4 |
| Jul 1, 2026 | Sean Maduck | See Remarks | Sale | 11,024 | $87.33 | $963K | Form 4 |
| Jul 1, 2026 | Sean Maduck | See Remarks | Sale | 2,801 | $88.51 | $248K | Form 4 |
| Jul 1, 2026 | Sean Maduck | See Remarks | Sale | 11,175 | $89.31 | $998K | Form 4 |
| Jun 17, 2026 | David L Mahoney | Director | Sale | 20,000 | $84.53 | $1.7M | Form 4 |
| Jun 16, 2026 | James N Wilson | Director | Sale | 4,177 | $82.69 | $345K | Form 4 |
| Jun 16, 2026 | James N Wilson | Director | Sale | 5,823 | $83.57 | $487K | Form 4 |
| Jun 15, 2026 | Atabak Mokari | CFO | Sale | 2 | $82.45 | $165 | Form 4 |
| Jun 15, 2026 | Atabak Mokari | CFO | Sale | 9,434 | $80.02 | $755K | Form 4 |
| Jun 15, 2026 | Atabak Mokari | CFO | Sale | 11,081 | $80.94 | $897K | Form 4 |
| Jun 15, 2026 | Atabak Mokari | CFO | Sale | 19,483 | $81.81 | $1.6M | Form 4 |
| Jun 2, 2026 | William Guyer | Chief Development Office | Sale | 20,000 | $70.60 | $1.4M | Form 4 |
| Jun 1, 2026 | Sean Maduck | See Remarks | Sale | 21,069 | $70.11 | $1.5M | Form 4 |
| Jun 1, 2026 | Sean Maduck | See Remarks | Sale | 3,931 | $70.75 | $278K | Form 4 |
| Jun 1, 2026 | Atabak Mokari | CFO | Sale | 40,000 | $70.00 | $2.8M | Form 4 |
| Jun 1, 2026 | Joseph K Belanoff | CEO | Sale | 12,837 | $69.74 | $895K | Form 4 |
| May 27, 2026 | Joseph Douglas Lyon | See Remarks | Sale | 5,000 | $65.00 | $325K | Form 4 |
| May 27, 2026 | Sean Maduck | See Remarks | Sale | 54,575 | $65.37 | $3.6M | Form 4 |
| May 27, 2026 | Sean Maduck | See Remarks | Sale | 20,425 | $66.16 | $1.4M | Form 4 |
| May 5, 2026 | William Guyer | Chief Development Office | Sale | 20,000 | $51.83 | $1M | Form 4 |
| May 1, 2026 | Joseph K Belanoff | CEO | Sale | 40,000 | $50.10 | $2M | Form 4 |
| Apr 7, 2026 | William Guyer | Chief Development Office | Sale | 20,000 | $40.97 | $819K | Form 4 |
| Mar 25, 2026 | Joseph K Belanoff | CEO | Sale | 26,198 | $50.07 | $1.3M | Form 4 |
| Mar 20, 2026 | William Guyer | Chief Development Office | Sale | 11,767 | $36.01 | $424K | Form 4 |
| Mar 17, 2026 | G Leonard Baker Jr | Director | Purchase | 24,218 | $33.56 | $813K | Form 4 |
| Mar 17, 2026 | G Leonard Baker Jr | Director | Purchase | 75,782 | $33.00 | $2.5M | Form 4 |
Latest 100 of 109 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sean Maduck | See Remarks | – | $25M | Nov 3, 2026 |
| Atabak Mokari | Chief Financial Officer | – | $18.7M | Jul 30, 2026 |
| David L Mahoney | Director | – | $13.9M | Aug 18, 2026 |
| William Guyer | Chief Development Officer | – | $11.6M | Aug 10, 2026 |
| Roberto Wandenkolk Vieira | President, Oncology | – | $8.1M | Nov 2, 2026 |
| Joseph K Belanoff | Chief Executive Officer, Director | – | $7.4M | Jun 1, 2026 |
| James N Wilson | Director | – | $5.1M | Oct 15, 2026 |
| G Leonard Baker Jr | Director | $3.3M | – | Mar 17, 2026 |
| Kimberly Park | Director | – | $3.3M | Aug 26, 2026 |
| Joseph Douglas Lyon | See Remarks | – | $3.2M | Oct 2, 2026 |
| Gary Charles Robb | Chief Business Officer | – | $1.2M | Aug 17, 2026 |
| Daniel N Swisher JR | Director | – | $111K | Nov 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CORT short interest
Moderate short interest. 8.3% of CORT shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.13M CORT shares were sold short, 8.3% of the shares outstanding, up 6.3% from the report before. At the average daily volume of 1.13M shares, buying them all back would take about 8.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.13M | 8.34% | +6% | 1.13M | 8.1 |
| Oct 15, 2026 | 8.59M | 7.95% | +1% | 698,644 | 12.3 |
| Sep 30, 2026 | 8.54M | 7.90% | -9% | 2.39M | 3.6 |
| Sep 15, 2026 | 9.35M | 8.65% | -1% | 944,042 | 9.9 |
| Aug 31, 2026 | 9.40M | 8.69% | -3% | 789,538 | 11.9 |
| Aug 14, 2026 | 9.70M | 8.97% | -1% | 927,931 | 10.4 |
| Jul 31, 2026 | 9.82M | 9.08% | +4% | 1.54M | 6.4 |
| Jul 15, 2026 | 9.44M | 8.80% | +9% | 1.09M | 8.7 |
| Jun 30, 2026 | 8.64M | 8.05% | +1% | 1.03M | 8.4 |
| Jun 15, 2026 | 8.57M | 7.98% | -3% | 969,260 | 8.8 |
| May 29, 2026 | 8.79M | 8.19% | -6% | 1.03M | 8.6 |
| May 15, 2026 | 9.32M | 8.68% | -13% | 1.48M | 6.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Corcept Therapeutics company events
Corcept Therapeutics filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Sep 23, 2026LeadershipSean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated of his decision to resign effective as of October 1, 2026. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jun 17, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the Company has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome. Filing
- Jun 3, 2026AnnouncementCorcept Therapeutics Incorporated learned that the United States Department of Justice had filed a Notice of Election to Decline Intervention in a civil qui tam action filed against the company, captioned U.S. et al. ex rel. Filing
- May 28, 2026LeadershipCorcept Therapeutics Incorporated held its 2026 Annual Meeting of Stockholders. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Mar 25, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has approved Lifyorli ™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal… Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Feb 19, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym ® does not infringe two of the Company’s patents concerning methods of safely… Filing
- Jan 22, 2026AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that ROSELLA, the Company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. Filing
- Dec 31, 2025AnnouncementCorcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Corcept Therapeutics financials
Famous investors that hold CORT
6 of the 50 well-known investors we track reported holding CORT in their latest 13F filing. The largest position is Jim Simons's, worth $559M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 4.85M | $559M | 0.8% | -8% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 268,180 | $30.9M | 0.1% | +366% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 239,818 | $27.6M | 0.0% | +120% |
| Israel Englander · Millennium Management | Q3 2026 | 152,576 | $17.6M | 0.0% | No change |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 21,293 | $2.5M | 0.0% | New |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 4,800 | $553K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CORT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.9% |
Questions about Corcept Therapeutics Inc (CORT) stock
Who owns the most CORT stock?
The largest reported owner of Corcept Therapeutics Inc (CORT) is BlackRock, Inc., with 11.6% of the company. In total, 420 funds and institutions reported holding CORT at the end of Q2 2026, together about 78% of the shares. See the largest owners.
Are CORT insiders buying or selling?
In the last 12 months, CORT insiders reported 2 open-market purchases worth $3.3M and 107 sales worth $97.7M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in CORT?
As of Oct 30, 2026, 9.13M CORT shares were sold short, 8.3% of the shares outstanding, up 6.3% from the report before. At the average daily volume of 1.13M shares, buying them all back would take about 8.1 trading days (days to cover). See the history.
Which famous investors hold CORT?
6 of the 50 well-known investors we track reported CORT in their latest 13F filing, including Jim Simons, Ray Dalio, Ken Griffin. The largest position is worth $559M. See all holders.
Executive pay
Corcept Therapeutics's chief executive was paid a total of $15.3M for the year ended Dec 31, 2025, up 55% from $9.9M the year before. In the last 12 months, Corcept Therapeutics's executives and directors bought $3.3M of stock on the open market and sold $97.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.